FDA Approves Rocket Pharma's Kresladi Gene Therapy for Ultra-Rare LAD-I After Setbacks on March 27, 2026 Approved gene therapy Kresladi Leukocyte adhesion deficiency type 1 Rocket Pharma ultra-rare disease United States Food and Drug Administration +